http://orcid.org/0000-0002-3325-8417
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Human epidermal growth factor receptor 2 (HER2) positive is a unique molecular subtype of breast cancer (BC) characterized by high malignancy and poor prognosis. Bilateral primary breast cancer (BPBC) harboring HER2 gene amplification is available to be detected among the BC survivors due to the increasing use of anti-HER2 adjuvant therapy. However, owing to the paucity of cases reported, knowledge of treating HER2-positive BPBC patients including the clinical behavior, histopathologic characteristics, anti-HER2 therapeutic response and disease outcome are not fully understood. Here we report a case of its kind receiving nonstandardized treatment during adjuvant stage. Upon tumor recurrence with liver metastasis, she received trastuzumab combined with chemotherapy and reached a PFS of 14.5 months in first-line treatment. While maintained trastuzumab plus carboplatin as second-line treatment progressed promptly, re-treatment of trastuzumab after lapatinib administration in third line can still benefit the patient. The present case report delineates an anti-HER2 path for a particular characterized patient, and also provides new evidence of trastuzumab re-usage after disease progression of prior anti-HER2 therapy.
Abbreviations
| APIs | = | Asian/Pacific Islanders |
| BBC | = | bilateral breast cancer |
| BC | = | breast cancer |
| BPBC | = | bilateral primary breast cancer |
| CFDA | = | China Food and Drug Administration |
| CT | = | computed tomography |
| ER | = | estrogen receptor |
| FISH | = | fluorescence in situ hybridization |
| HER2 | = | human epidermal growth factor receptor 2 |
| IDC | = | infiltrating ductal carcinoma |
| mBBC | = | metachronous bilateral breast cancer |
| mBC | = | metastatic breast cancer |
| MDT | = | multidisciplinary team |
| PFS | = | progression free survival |
| PR1 | = | progesterone receptor |
| PR2 | = | partial response |
| sBBC | = | synchronous bilateral breast cancer. |
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Acknowledgments
The authors sincerely thank the patient for her contribution to the publication of this case report.
Ethical statements
The report of this study was approved by the ethics committee of our institution, and written informed consent was obtained from the patient.